Company: IXHL
Filing Date: 2025-04-28
Form Type: 424B3
Source: 0001213900-25-036065
Chunk: 15

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: 424B3
Chunk 15
---
 that contains reports and information statements, and other information
regarding issuers that file electronically with the SEC at http://www.sec.gov.

<div align='center'>4</div>

THE OFFERING

| Common Stock offered by selling stockholders hereunder |     | 75,902,171 shares, consisting of (i) 9,687,045 shares of Common Stock,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 (ii) 1,887,045 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants to purchase shares of Common Stock, and (iii)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 64,328,081 shares of Common Stock issuable upon the exercise of the Series A Warrants to purchase shares of Common Stock. The Series A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 Warrants are not currently exercisable and will be exercisable following the date of Stockholder Approval.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Risk Factors:                                          |     | Investing in our securities is highly speculative and involves a high degree of risk. You should carefully consider the information set forth in the “Risk Factors” section on page 6 before deciding to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Use of proceeds                                        |     | We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of Shares by the selling stockholders. We will likely only receive nominal proceeds of $0.0001 per share upon the cash exercise of the Pre-Funded Warrants. Though we would receive the proceeds for the cash exercise of the Series A Warrants per their terms, we are unlikely to receive any cash proceeds from the exercise of the Series A Warrants as the Series A Warrants may be exercised following stockholder approval on a zero exercise price basis where the holder will be eligible to receive, for each share of Common Stock issuable upon exercise of the Series A Warrant, three shares of our Common Stock without the payment of any exercise price. To the extent we receive any proceeds, we intend to use the proceeds for working capital and general corporate purposes. See “Use of Proceeds” on page 10 of this prospectus for more information. |
| Nasdaq Global Market symbol:                           |     | IXHL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Risk Factors                                           |     | Any investment in shares of our Common Stock is speculative and involves a high degree of risk. You should carefully consider the information set